| Alimera Sciences is a pharmaceutical company that focuses on the commercialization and development of ophthalmic pharmaceuticals. Co. focuses on diseases affecting the retina. Co.'s commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide in the eye, for up to 36 months. ILUVIEN is also used in certain countries in the European Economic Area to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. LUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a needle, which allows for a self-sealing wound. We show 53 historical shares outstanding datapoints in our ALIM shares outstanding history coverage, used to compute ALIM market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALIM market cap history over the course of time is important for investors
interested in comparing ALIM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALIM versus a peer is one thing; comparing
ALIM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALIM can fluctuate over the course of history.
With this page we aim to empower investors researching ALIM by allowing them to research the ALIM market cap history.